• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Abcuro Publications
    • Other Publications
  • Pipeline
    ▼
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact
About

About

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Abcuro Publications
    • Other Publications
  • Pipeline
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact

Balogh, Peter

September 1, 2026

Peter Balogh is an Analyst with the Investment team at RA Capital Management. Peter’s primary responsibilities are to conduct due diligence on biotechnology companies and advise RA Capital’s portfolio companies on many aspects of program and pipeline strategy. Peter holds a BS in Biology from the University of North Carolina at Chapel Hill.

Peter Balogh

Observer
Analyst, RA Capital

x

Peter Balogh

Observer
Analyst, RA Capital

Peter Balogh is an Analyst with the Investment team at RA Capital Management. Peter’s primary responsibilities are to conduct due diligence on biotechnology companies and advise RA Capital’s portfolio companies on many aspects of program and pipeline strategy. Peter holds a BS in Biology from the University of North Carolina at Chapel Hill.

Privacy Site Credits Terms of Use

© 2026 Abcuro